Author:
Hamurcu Zuhal,Delibaşı Nesrin,Nalbantoglu Ufuk,Sener Elif Funda,Nurdinov Nursultan,Tascı Bayram,Taheri Serpil,Özkul Yusuf,Donmez-Altuntas Hamiyet,Canatan Halit,Ozpolat Bulent
Funder
The Scientific and Technological Research Council ?T?B?TAK, Research Fund of the Erciyes University
Publisher
Springer Science and Business Media LLC
Subject
Genetics(clinical),Drug Discovery,Molecular Medicine
Reference52 articles.
1. PDQ Cancer Information Summaries. Bethesda (MD): National Cancer Institute (US); 2002–2018. Breast Cancer Treatment (PDQ®): Patient Version, PDQ Adult Treatment Editorial Board 2018
2. Narrandes S, Huang S, Murphy L, Xu W (2018) The exploration of contrasting pathways in triple negative breast cancer (TNBC). BMC Cancer 18:22
3. Cazzaniga ME, Airoldi M, Arcangeli V, Artale S, Atzori F, Ballerio A, on behalf of; EVA Study Group (2017) Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2-) advanced breast cancer patients: new insights beyond clinical trials. The EVA study. Breast 35:115–121
4. Guo W, Lin L, He X, He F, Wang C, Chen N, Wang Y (2017) Biomarkers of DNA repair and related pathways: significance of treatment in triple-negative breast cancer. Crit Rev Oncog 22:427–437
5. Engebraaten O, Vollan HKM, Børresen-Dale AL (2013) Triple-negative breast cancer and the need for new therapeutic targets. Am J Pathol 183:1064–1074
Cited by
42 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献